A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.

MLA

Koutsilieris, M., et al. “A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients.” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, Dec. 2001, pp. 5729–36. EBSCOhost, https://doi.org/10.1210/jcem.86.12.8119.

APA

Koutsilieris, M., Mitsiades, C., Dimopoulos, T., Ioannidis, A., Ntounis, A., & Lambou, T. (2001). A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. The Journal of Clinical Endocrinology and Metabolism, 86(12), 5729–5736. https://doi.org/10.1210/jcem.86.12.8119

Chicago

Koutsilieris, M, C Mitsiades, T Dimopoulos, A Ioannidis, A Ntounis, and T Lambou. 2001. “A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients.” The Journal of Clinical Endocrinology and Metabolism 86 (12): 5729–36. doi:10.1210/jcem.86.12.8119.